The ongoing regulatory dispute centers on whether the fitness wearable’s proprietary algorithm meets the clinical definition of a medical device, or merely displays arbitrarily generated numbers formatted to look like cardiovascular data.
At the recent STAT Breakthrough Summit, a top Whoop executive tentatively disclosed what appears to be an ongoing regulatory dispute with the Food and Drug Administration, though representatives stressed that the existence of the dispute itself remains subject to further peer review. The controversy surrounds a recently introduced biometric feature that claims to measure users' blood pressure, an assertion federal regulators currently classify as an interesting but unsubstantiated hypothesis.
The FDA’s warning letter, which was issued with a standard 95% confidence interval, indicated that the wearable’s new feature may not be measuring blood pressure in the traditional clinical sense. Specifically, agency researchers noted a confounding variable wherein the device relies entirely on green flashing lights and algorithmic extrapolation rather than an inflatable cuff, a methodology that has not yet demonstrated statistically significant efficacy in detecting human vascular resistance.
Independent cardiologists remain sharply divided—within an acceptable margin of error—over whether a silicone wristband can accurately infer arterial pressure from ambient sweat and movement data.
While the initial observational cohort showed the Whoop strap successfully displayed a systolic and diastolic integer on a smartphone screen, we lacked the longitudinal endpoints to confirm if those integers corresponded to the specific patient wearing the device.
In response to the regulatory inquiry, Whoop has initiated a series of double-blind, placebo-controlled discussions with federal regulators. The company maintains that its proprietary software shows a promising, if causally ambiguous, association with cardiovascular health. A preliminary internal white paper suggested that users who read the FDA warning letter experienced an immediate, verifiable spike in their actual blood pressure, though researchers caution that this secondary effect requires a larger sample size to confirm causality.
Until a regulatory consensus is reached, the FDA recommends a highly conservative approach to fitness trackers. Consumers are advised to treat any biometric data generated by the optical sensor as a novel hypothesis requiring further independent testing. Medical professionals suggest that users experiencing a reassuring reading of 120 over 80 should not immediately assume they are alive, pending a formal clinical electrocardiogram.